BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

Thermo Fisher opens ultra-cold facility in EU to accelerate advanced therapies development

June 3, 2024 | News

New facility in Bleiswijk, Netherlands offers a comprehensive range of cold and ultra-cold services



US-based Thermo Fisher Scientific Inc. has opened a new clinical and commercial ultra-cold facility in the European Union (EU), expanding its clinical trial network in Europe to help accelerate the development of advanced therapies.

The new current good manufacturing practice (cGMP) facility in Bleiswijk, Netherlands provides pharma and biopharma customers tailored, end-to-end support throughout the clinical supply chain for high-value therapies, including cell and gene therapies, biologics, antibodies and vaccines.

To meet increasing demand from cell and gene therapy clinical trials in Europe, this state-of-the-art facility builds on the company's market leadership and global CDMO capabilities in bioservices and specialty logistics services, including biorepository solutions and critical material storage. The facility enables customers to meet clinical trial requirements regardless of scale or phase by leveraging its highly skilled and talented local workforce to partner with new and emerging biotech and established pharmaceutical companies.

The site, 30 minutes outside of Amsterdam, offers clinical and commercial packaging services for cell and gene therapy products from development to commercialization, as well as end to end biorepository storage solutions and associated supply chain services. Capabilities include 5,000-square-meters (54,000 square feet) of ambient to cryogenic storage, ancillaries, and cold chain packaging, labeling, distribution as well as clinical QP release services.